Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation Through 2042
Summary
Nexalin Technology announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia. The patent provides core intellectual property protection through 2042 and covers methods involving dynamic frequency stimulation designed for three of the largest underserved markets in mental health.
Why it matters
This patent issuance significantly strengthens Nexalin's competitive position in non-invasive frequency-based deep-brain neurostimulation and creates a substantial barrier to entry for competitors. By protecting its core dynamic frequency stimulation approach across anxiety, depression, and insomnia collectively representing enormous unmet medical need, Nexalin establishes the foundation for long-term commercial exclusivity and potential platform expansion.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial